ClinicalTrials.gg
RecruitingNCT07282613REIMAGINEYOUNGUpdated Oct 19, 2026

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes

A Phase 3 interventional study of CagriSema (Cagrilintide B and Semaglutide I) and Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Recruiting at 58 sites in 10 countries. Open to participants aged 10 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 19, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
10 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing cagrilintide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 4 of them phase 3. cagrilintide · Diabetes Mellitus, Type 2.

Planned enrollment
14th of 15
80 · median 274
Started
2026
with 3 others
Phase 3
10 of 15
3 open now
Registered
12th of 15
by date
Lead sponsor
15 of 15
Novo Nordisk A/S

Among the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2, this one is the 14th largest by planned enrollment, is one of 4 that started in 2026, is one of 10 in phase 3, and was the 12th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cagrilintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 10 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing cagrilintide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this clinical study is to look into how well a study medicine called CagriSema helps children and adolescents living with diabetes lower their blood sugar and body weight. The study has 2 parts: in the first part participant will get either CagriSema or placebo, and in the second part participant will get CagriSema. In the first part, which treatment participant gets is decided by chance and second part is open label and all participants will get CagriSema during this part. The study will last for about 1 year and 3 months.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
10 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • of parent(s) or legally acceptable representative (LAR) of participant and child assent, as age-appropriate, obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.

    • The parent(s) or LAR of the child must sign and date the Informed Consent Form (according to local requirements)
    • The child must sign and date the Child Assent Form or provide oral assent (according to local requirements)
  • Male or female.
  • Age 10 to \< 18 years at the time of signing the informed consent.
  • Diagnosed with T2D (according to the latest International Society for Pediatric and Adolescent Diabetes [ISPAD] criteria) ≥ 30 days before screening.
  • Treated with diet and exercise counselling alone or with a stable daily dose(a), in addition to diet and exercise counselling, of any of the following antidiabetic drugs or combination regimens:

    • Insulin (any regimen)
    • Metformin
    • SGLT2i
  • 6.5%-11.0% (48 mmol/mol - 97 mmol/mol) (both inclusive) as determined by central laboratory at screening.
  • Body weight ≥ 45 kg and ≥ 85th percentile(b). BMI will be calculated in the electronic case report form based on height and body weight at screening.

    • (a) For metformin, a stable dose is defined as at least 1000 mg daily or the maximum tolerated dose for ≥ 56 days prior to screening. For Sodium-Glucose Transport protein 2 inhibitor (SGLT2i), a stable dose is defined as the same total daily dose for ≥ 56 days prior to screening. For insulin, it is defined as the dose ± 25% of that taken at screening for ≥ 30 days prior to screening.
    • (b) Based on sex-specific BMI-for-age percentiles for the given country or region. If not available for the country or region, the respective charts or tables on cdc.gov may be used.

Key Exclusion Criteria:

  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using a highly effective method.
  • Treatment with any antidiabetic or anti-obesity medication (irrespective of indication) other than stated in the inclusion criteria within 90 days before screening.
  • Known or previous diagnosis of hypoparathyroidism.
  • Previous or planned (during the study period) obesity treatment with surgery or a weight loss device. However, the following are allowed: (1) liposuction and/or abdominoplasty, if performed >1 year before screening, (2) lap banding, if the band has been removed >1 year before screening, (3) intragastric balloon, if the balloon has been removed >1 year before screening or (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed > 1 year before screening.
  • Positive insulinoma associated-protein 2 (IA-2) antibodies or anti-glutamic acid decarboxylase (anti-GAD) antibodies as determined by central laboratory at screening or in medical history.
  • Recurrent severe hypoglycaemic episodes within the last year as judged by the investigator.
  • Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question 8.
  • Uncontrolled and potentially unstable diabetic retinopathy maculopathy. Verified by a fundus examination and optical coherence tomography (OCT) assessment performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Part 1: CagriSema

    Participants will receive CagriSema (Cagrilintide B + Semaglutide I) subcutaneously once weekly for 26 weeks in Part 1.

    Drug: CagriSema (Cagrilintide B and Semaglutide I)

  • Placebo comparator
    Part 1: Placebo

    Participants will receive placebo matched to CagriSema (Cagrilintide B + Semaglutide I) subcutaneously once weekly for 26 weeks in Part 1.

    Drug: Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)

  • Experimental
    Part 2: CagriSema

    Participants who received placebo in Part 1 will receive CagriSema (Cagrilintide B + Semaglutide I) subcutaneously once weekly for 26 weeks in Part 2.

    Drug: CagriSema (Cagrilintide B and Semaglutide I)

Interventions

  • DrugCagriSema (Cagrilintide B and Semaglutide I)

    Drug page: Cagrilintide

    Cagrilintide B and Semaglutide I will be administered subcutaneously using DV3384 pen-injector.

  • DrugPlacebo matched to CagriSema (Cagrilintide B and Semaglutide I)

    Placebo matched to Cagrilintide B and Placebo matched to Semaglutide I will be administered subcutaneously using DV3384 pen-injector.

This study also gives Semaglutide. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Change in glycated haemoglobin (HbA1c)

    Measured as percentage (%) of HbA1c.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

Secondary outcomes

  1. Relative change in body mass index (BMI)

    Measured as percentage.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  2. Number of participants with achievement of HbA1c target values of less than (<) 7.0% (< 53 millimole per mole [mmol/mol])

    Measured as count of participants.

    Time frame: At end of double-blinded treatment (week 26)

  3. Number of participants with achievement of HbA1c target values of less than or equal to (≤) 6.5% (≤48 mmol/mol)

    Measured as count of participants.

    Time frame: At end of double-blinded treatment (week 26)

  4. Change in time in range (TIR) 3.9-10.0 millimole per liter (mmol/L) (70-180 milligram per deciliter (mg/dL) measured using continuous glucose monitoring (CGM)

    Measured as percentage of time.

    Time frame: From baseline (collected during week -3, -2 and -1) to end-of-double-blinded treatment (collected during week 22, 23, 24, and 25)

  5. Change in time in tight target range (TITR) 3.9-7.8 mmol/L (70-140 mg/dL) measured using CGM

    Measured as percentage of time.

    Time frame: From baseline (collected during week -3, -2 and -1) to end-of-double-blinded treatment (collected during week 22, 23, 24, and 25)

  6. Change in time above range (TAR) greater than (>) 10.0 mmol/L (> 180 mg/dL) measured using CGM

    Measured as percentage of time.

    Time frame: From baseline (collected during week -3, -2 and -1) to end-of-double-blinded treatment (collected during week 22, 23, 24, and 25)

  7. Change in TAR greater than (>) 13.9 mmol/L (> 250 mg/dL) measured using CGM

    Measured as percentage of time.

    Time frame: From baseline (collected during week -3, -2 and -1) to end-of-double-blinded treatment (collected during week 22, 23, 24, and 25)

  8. Change in mean sensor glucose concentration measured by CGM

    Measured as mmol/L.

    Time frame: From baseline (collected during week -3, -2 and -1) to end-of- double-blinded treatment (collected during week 22, 23, 24, and 25)

  9. CGM: Within-day glycaemic variability (% coefficient of variation)

    Measured as percentage.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  10. Number of participants with incidence of glycaemic rescue therapy

    Measured as count of participants

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  11. Change in fasting plasma glucose

    Measured as mmol/L.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  12. Number of participants with achievement of greater than or equal to (≥) 5% BMI reduction

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  13. Number of participants with achievement of ≥ 10% BMI reduction

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  14. Number of participants with achievement of ≥ 15% BMI reduction

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  15. Relative change in body weight

    Measured as percentage of body weight.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  16. Change in BMI standard deviation score (SDS)

    Measured as score on scale.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  17. Change in waist circumference

    Measured as centimetre (cm).

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  18. Change in waist-to-height ratio

    Measured as ratio.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  19. Change in systolic blood pressure

    Measured as millimetre of mercury (mmHg).

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  20. Change in diastolic blood pressure

    Measured as mmHg.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  21. Ratio to baseline in lipid: total cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  22. Ratio to baseline in lipid: high density lipoprotein (HDL) cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  23. Ratio to baseline in lipid: low density lipoprotein (LDL) cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  24. Ratio to baseline in lipid: very low density lipoprotein (VLDL) cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  25. Ratio to baseline in lipid: triglycerides

    Measured as ratio.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  26. Ratio to baseline in lipid: Non-HDL cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  27. Change in alanine aminotransferase (ALT)

    Measured as units per liter (U/L).

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26) and end of extension phase treatment (week 52)

  28. Apparent clearance (CL/F) of cagrilintide and semaglutide

    Measured as liter per hour (L/h).

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  29. Average concentration (Cavg) of cagrilintide and semaglutide at steady state

    Measured as nanomole per liter (nmol/L).

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  30. Change in insulin dose

    Measured as units (U).

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  31. Number of participants with achievement of sustained insulin dose = 0 U

    Measured as count of participants.

    Time frame: At end of double-blinded treatment (week 26)

  32. Ratio to baseline in urine albumin-creatinine ratio (UACR)

    Measured as ratio.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  33. Ratio to baseline in biomarker related to glucose metabolism: fasting C-peptide

    Measured as ratio.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  34. Ratio to baseline in biomarker related to glucose metabolism: fasting insulin

    Measured as ratio.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  35. Ratio to baseline in biomarker related to glucose metabolism: fasting proinsulin

    Measured as ratio.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  36. Ratio to baseline in biomarker related to glucose metabolism: fasting glucagon

    Measured as ratio.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  37. Ratio to baseline in high sensitivity C-reactive protein (hsCRP)

    Measured as ratio.

    Time frame: From baseline (week 0) to end of double- blinded treatment (week 26)

  38. Ratio to baseline in free fatty acids

    Measured as ratio.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  39. Ratio to baseline in leptin

    Measured as ratio.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  40. Ratio to baseline in soluble leptin receptor

    Measured as ratio.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  41. Ratio to baseline in leptin to soluble leptin receptor ratio

    Measured as ratio.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  42. Change in aspartate aminotransferase (AST)

    Measured as U/L.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26) and end of extension phase treatment (week 52)

  43. Change in alkaline phosphatase (ALP)

    Measured as U/L.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26) and end of extension phase treatment (week 52)

  44. Change in bilirubin

    Measured as U/L.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26) and end of extension phase treatment (week 52)

  45. Change in HbA1c

    Measured as percentage of HbA1c.

    Time frame: From baseline (week 0) to end of extension phase treatment (week 52)

  46. Number of clinically significant hypoglycaemic episodes (level 2) (< 3.0 mmol/L (54 mg/dL) confirmed by blood glucose [BG] meter)

    Measured as count of episodes.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  47. Number of severe hypoglycaemic episodes (level 3) - severe hypoglycaemia being defined as severe cognitive impairment requiring assistance by another person to administer carbohydrates, glucagon, or intravenous glucose

    Measured as count of episodes.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  48. Change in percentage of time below range (TBR) < 3.0 mmol/L (< 54 mg/dL) measured using CGM

    Measured as percentage of time.

    Time frame: At end of double-blinded treatment (collected during week 22, 23, 24, and 25)

  49. Change in TBR < 3.9 mmol/L (< 70 mg/dL) measured using CGM

    Measured as percentage of time.

    Time frame: At end of double-blinded treatment (collected during week 22, 23, 24, and 25)

  50. Number of treatment-emergent adverse events

    Measured as count of events.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

  51. Height velocity

    Measured as cm/year.

    Time frame: At end of double-blinded treatment (week 26)

  52. Change in height SDS

    Measured as score on scale.

    Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)

07

Study locations

31 of 58 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Sep 2029, 37 months after the start.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 37 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2025
First posted
Dec 15, 2025
StartActual
Aug 4, 2026
Primary completionEst.
Sep 7, 2029
CompletionEst.
Mar 30, 2030
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Hospital Universitário Walter Cantídio is now Recruiting
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Hospital Universitário Walter Cantídio is now Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07282613
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Dec 15, 2025
Start date
Aug 4, 2026
Primary completion
Sep 7, 2029 (estimated)
Completion
Mar 30, 2030 (estimated)
Last update
Oct 19, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency dept. 2834
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cagrilintide

Start the discussion